相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A Phase I, Pharmacokinetic and Pharmacodynamic Study on Vorinostat in Combination with 5-Fluorouracil, Leucovorin, and Oxaliplatin in Patients with Refractory Colorectal Cancer
Marwan G. Fakih et al.
CLINICAL CANCER RESEARCH (2009)
Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease
Thomas S. Lin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma
M. Crump et al.
ANNALS OF ONCOLOGY (2008)
Phase I study of flavopiridol in combination with paclitaxel and carboplatin in patients with non-small-cell lung cancer
Saby George et al.
CLINICAL LUNG CANCER (2008)
Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma
Paul Richardson et al.
LEUKEMIA & LYMPHOMA (2008)
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes
Guillermo Garcia-Manero et al.
BLOOD (2008)
Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells
Clint Mitchell et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors
M. N. Fornier et al.
CLINICAL CANCER RESEARCH (2007)
Phase I and pharmacokinetic study of vorinostat, A histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies
Suresh S. Ramalingam et al.
CLINICAL CANCER RESEARCH (2007)
Enhancement of cisplatin induced apoptosis by suberoylanilide hydroxamic acid in human oral squamous cell carcinoma cell lines
Jun Shen et al.
BIOCHEMICAL PHARMACOLOGY (2007)
Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia
John C. Byrd et al.
BLOOD (2007)
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer
Nichole Boyer Arnold et al.
CLINICAL CANCER RESEARCH (2007)
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma, (CTCL)
Madeleine Duvic et al.
BLOOD (2007)
A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer
Eric H. Rubin et al.
CLINICAL CANCER RESEARCH (2006)
A liquid chromatography-electrospray ionization tandem mass spectrometric assay for quantitation of the histone deacetylase inhibitor, vorinostat (suberoylanilide hydroxamicacid, SAHA), and its metabolites in human serum
Robert A. Parise et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2006)
Cyclin-dependent kinase pathways as targets for cancer treatment
GI Shapiro
JOURNAL OF CLINICAL ONCOLOGY (2006)
Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-κB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-jun n-terminal kinase 1 activation
Y Dai et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer
WK Kelly et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol
MA Shah et al.
CLINICAL CANCER RESEARCH (2005)
A Bayesian evaluation of enrolling additional patients at the maximum tolerated dose in phase I trials
M Gönen
CONTEMPORARY CLINICAL TRIALS (2005)
Contribution of disruption of the nuclear factor-κB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol
N Gao et al.
MOLECULAR PHARMACOLOGY (2004)
Histone deacetylase inhibitors: From chromatin remodeling to experimental cancer therapeutics
J Arts et al.
CURRENT MEDICINAL CHEMISTRY (2003)
CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment
A Trotti et al.
SEMINARS IN RADIATION ONCOLOGY (2003)
Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA)
J Almenara et al.
LEUKEMIA (2002)
Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors
GK Schwartz et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer
RW Johnstone
NATURE REVIEWS DRUG DISCOVERY (2002)
Histone deacetylases and cancer: Causes and therapies
PA Marks et al.
NATURE REVIEWS CANCER (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
